Rate of return on biopharma R&D late stage pipeline 2013-2022
This statistic shows the internal rate of return (IRR) on biopharmaceutical late-stage R&D pipeline from 2013 to 20222. The data is based on 12 large-cap and four mid-to-large-cap biopharma companies. The rate of return decreased from 2014 to 2019, but saw an increase in 2020 and 2021, before another sharp decline in 2022.
